Everlasting founder Deepinder Goyal’s healthtech enterprise Temple is working with the Sri Sri Institute for Superior Analysis (SSIAR), the analysis division of the Artwork of Residing Basis, to review the results of various meditation practices.

The analysis will use Entropy, a metric that Temple describes as a brand new biomarker, to look at physiological modifications throughout meditation.

Goyal stated Temple had noticed Entropy falling in actual time throughout meditation even when coronary heart fee remained largely unchanged.

“Entropy is a brand new biomarker on Temple that additionally measures your physique’s (para)sympathetic state, and we’ve seen it drop actual time throughout meditation, whereas HR stays flat,” he stated in a put up on X.

Entropy x Meditation

I’m glad to have @temple and Sri Sri Institute for Superior Analysis (SSIAR), the analysis arm of Artwork of Residing, collaborate to measure the impact of various meditation practices by Entropy.

Entropy is a brand new biomarker on @temple that additionally measures… pic.twitter.com/2Tx1Ht2vS7

— Deepinder Goyal (@deepigoyal) September 13, 2026

“I’m trying ahead to seeing which meditation apply produces the deepest parasympathetic response.”

Goyal stated he visited the Artwork of Residing ashram as a part of the analysis and had sought to contain religious chief Sri Sri Ravi Shankar within the research.

“All I knew about Gurudev till immediately was that he taught meditation to tens of millions of individuals,” Goyal stated.

In keeping with Goyal, Ravi Shankar advised him that “machines don’t work on me” and inspired the Temple staff to hold out the research with different skilled meditators on the ashram.

Goyal described Temple as a “science first organisation” and stated the outcomes of its research with the Artwork of Residing shall be printed quickly.

Temple is growing a wearable gadget that collects physiological and wellness knowledge. Its privateness coverage lists measures together with coronary heart fee, heart-rate variability, respiratory fee, exercise, sleep and restoration metrics.

Temple’s phrases of use state that the gadget shouldn’t be a medical gadget and is meant for basic wellness and informational functions somewhat than for diagnosing, treating, curing or stopping medical circumstances.

Goyal has beforehand described Entropy as a measure designed to indicate modifications within the physique in actual time. In June, he stated Temple had in contrast the metric with readings from a metabolic cart throughout greater than 100 cardio periods. 

Temple has additionally been strengthening its medical and scientific staff forward of the wearable’s launch.

In August, Goyal introduced that Temple was buying Longevous, an evidence-based longevity drugs apply primarily based in London.

Longevous founders Robert Mohr and Avi Roy, together with their staff, are becoming a member of Temple full time.

Mohr has joined as chief medical officer. Goyal stated he’s a board-certified doctor with practically twenty years of medical expertise and had moved from emergency drugs into evidence-based longevity drugs.

Roy has joined as head of science. He’s an Oxford-trained biomedical scientist and a co-founder of Founders Well being and UDA. He was beforehand a analysis fellow on the Centre for the Development of Sustainable Medical Innovation on the College of Oxford.

Goyal stated Mohr and Roy had used Temple for 2 months and labored with its science staff to pressure-test Entropy and the information collected by the gadget.

He stated the pair later grew to become concerned in Temple’s validation work and reviewed its first scientific manuscripts earlier than submission.